• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Nebivolol and incident cardiovascular events in hypertensive patients compared with nonvasodilatory beta blockers
Conclusion: The vasodilatory beta blocker nebivolol was associated with reduced incident cardiovascular events compared with nonvasodilatory beta blockers. Additional study of other beta blockers is necessary to determine if this is a vasodilatory beta blocker class effect or is specific to nebivolol. Graphical abstract: http://links.lww.com/HJH/B916
Source: Journal of Hypertension - May 1, 2022 Category: Cardiology Tags: ORIGINAL ARTICLES Source Type: research

Beta-blockers in hypertension: overview and meta-analysis of randomized outcome trials
Conclusion: Compared with other antihypertensive agents, beta-blockers appear to be substantially less protective against stroke and overall mortality. However, they exhibit a substantial risk-reducing ability for all events when prescribed to lower BP in patients with modest or more clear BP elevations, and therefore can be used as additional agents in hypertensive patients.
Source: Journal of Hypertension - August 13, 2020 Category: Cardiology Tags: REVIEWS AND META-ANALYSES Source Type: research

Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 14 – effects of different classes of antihypertensive drugs in older and younger patients overview and meta-analysis
Conclusion: Most BP-lowering classes are equally effective in preventing risk of fatal and nonfatal cardiovascular events both in older and younger patients, whereas beta-blockers, though being equally effective as the other agents in patients younger than 65, loose some of their effectiveness at an older age.
Source: Journal of Hypertension - June 28, 2018 Category: Cardiology Tags: Meta-Analyses Source Type: research

Prestroke treatment with beta-blockers for hypertension is not associated with severity and poor outcome in patients with ischemic stroke: data from a national stroke registry
Background: Beta-blockers are not recommended as the initial therapy for hypertension. Reports on associations between use of beta-blockers and stroke severity are inconclusive. We assessed associations between prestroke use of beta-blockers and stroke severity, poststroke disability and death in a large group of hypertensive patients hospitalized with acute ischemic stroke. Methods: All 3915 patients with ischemic stroke, treated prestroke for hypertension and registered in the National Acute Stroke ISraeli, were included. Treatment for hypertension was classified by medication type (beta-blockers, diuretics, calcium ant...
Source: Journal of Hypertension - March 2, 2017 Category: Cardiology Tags: ORIGINAL PAPERS: Therapeutic aspects Source Type: research

Blood pressure treatment levels and choice of antihypertensive agent in people with diabetes mellitus: an overview of systematic reviews
Conclusion: The available evidence supports treatment in people with type 2 diabetes and SBP more than 140 mmHg, using any of the major antihypertensive drug classes.
Source: Journal of Hypertension - January 31, 2017 Category: Cardiology Tags: Reviews Source Type: research

Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses
Conclusions: The results of all available evidence from head-to-head drug class comparisons do not allow the formulation of a fixed paradigm of drug choice valuable for all hypertensive patients, but the differences found may suggest specific choices in specific conditions, or preferable combinations of drugs.
Source: Journal of Hypertension - June 5, 2015 Category: Cardiology Tags: Reviews Source Type: research

Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs – Overview and meta-analyses
Conclusion: BP lowering by all classes of antihypertensive drugs is accompanied by significant reductions of stroke and major cardiovascular events. This supports the concept that reduction of these events is because of BP lowering per se rather than specific drug properties. However, evidence of risk reduction of other events and particularly mortality was obtained so far with some drug classes only. As a result of marked differences in the trial design, total cardiovascular risk, SBP/DBP differences and statistical power, comparisons of meta-analyses of different drug-specific placebo-controlled RCTs appear unwarranted.
Source: Journal of Hypertension - January 6, 2015 Category: Cardiology Tags: Reviews and Meta-Analyses Source Type: research